References
- Faderl S, Kantarjian H M, Thomas D A, Cortes J, Giles F, Pierce S, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000; 36: 263–273
- Cornelissen J J, Carston M, Kollman C, King R, Dekker A W, Lowenberg B, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572–1577
- Lee K H, Lee J H, Choi S J, Lee J H, Seol M, Lee Y S, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19: 1509–1516
- Hofmann W K, Komor M, Hoelzer D, Ottmann O G. Mechanisms of resistance to STI571 (imatinib) in Philadelphia-chromosome positive acute leukemia lymphoblastic leukemia. Leuk Lymphoma 2004; 45: 655–660
- O'Hare T, Walters D K, Stoffregen E P, Jia T, Manley P W, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505
- Cortes J, Rousselot P, Kim D W, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207–3213
- Talpaz M, Shah N P, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541
- Thiede C, Bornhauser M, Ehninger G. Evaluation of STR informativity for chimerism testing – comparative analysis of 27 STR systems in 203 matched related donor recipient pairs. Leukemia 2004; 18: 248–254
- Jabbour E, Cortes J, Kantarjian H, Giralt S, Jones D, Jones R, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421–1423
- Dompret H, Ottmann O G, Rosti G, Simonsson B, Larson R A, Gollerker A, et al. Dasatinib (SPRYCEL) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant or -intolerant: updated results from the CA180-015 ‘START-L’ study. ASH Annual Meeting Abstracts 2006; 108: 286
- Shimoni A, Kroger N, Zander A R, Rowe J M, Hardan I, Avigdor A, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–297